Gilead to get attorney fees in hepatitis C patent fight with Merck

Aug 11 (Reuters) - Gilead Sciences Inc is entitled

to receive the attorney fees it incurred related to hepatitis C

patent litigation with drugmaker Merck & Co Inc, a U.S.

district judge has ruled.

Read more